Milepoint was created for life sciences professionals by life sciences professionals. Our team has been at the forefront of the development of novel drugs, medical devices, and other technologies and we are ready to share our experience with you.
Founder & Partner
Przemek is an experienced executive advisor with over 100 completed strategy and commercial development projects. His work spans areas such as asset and portfolio strategy, new market entry, commercial due diligence and licensing, as well as regulatory approval, and market access strategy. Przemek has worked with many of the Top 20 pharmaceutical and medical devices companies, including on blockbuster and cutting-edge novel therapies.
Prior to founding milepoint, Przemek co-led the London office of Kx Advisors, a premier global healthcare strategy consultancy, and worked as a specialist consultant at McKinsey & Company, focusing on international mergers and acquisitions and regulatory strategy.
Przemek holds an MSc in Management of Innovation from the Rotterdam School of Management, Erasmus University, as well as a Bachelor of Business Administration, and a Bachelor of Laws from the University of Granada. He also completed post-graduate training in Private Equity and Venture Capital at IE Business School, Madrid.
As a Consultant, Ellen partners with milepoint advisors and executives to provide medtech and biotechnology companies with critical insights and analysis on strategy and commercial development of novel therapies and diagnostics. She combines her business acumen with a profound passion for life sciences, with a focus on underserved patient populations in the field of rare and neglected diseases, women's health, and pediatric indications, among others.
Prior to joining milepoint, Ellen worked as a strategy and marketing intern at Temple Therapeutics, a biotechnology company which targets indications that predominantly affect women. In her role, Ellen supported the CEO in defining strategies in the field of marketing.
Ellen holds an MSc in Strategic Management (cum laude) and an MSc in Management of Innovation (cum laude) from the Rotterdam School of Management, Erasmus University. She also earned a BSc in International Business (cum laude) from the School of Business and Economics, Maastricht University. She wrote both her master theses on the biotechnology industry, developing in-depth insights on M&A and licensing agreements, and on social biotechnology ventures.